IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, July 2026
Impact Factor: 8.2

Role of Efflux Pump Over Expression in Ethambutol Resistance among Drug-Resistant Mycobacterium Tuberculosis

Hariom Kushwaha[1], Dr. Naveen Kumar Singh[2]
[1]Research Scholar, [2]Professor
Department of Microbiology
Vikrant University, Gwalior (M.P.)

Abstract: *Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), remains one of the leading infectious diseases worldwide despite the availability of effective chemotherapy. The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) TB has significantly complicated treatment strategies. Ethambutol (EMB), a first-line anti-tubercular drug, inhibits the synthesis of the mycobacterial cell wall by targeting arabinosyl transferase enzymes encoded by the embCAB operon. Although mutations in the embB gene are the primary mechanism of EMB resistance, increasing evidence suggests that overexpression of bacterial efflux pumps also contributes significantly to reduced drug susceptibility.*

Efflux pumps actively transport antimicrobial agents out of bacterial cells, lowering intracellular drug concentrations and enabling bacterial survival. Several efflux pump genes, including Rv1258c (Tap), efpA, pstB, Rv1819c, drrA, and mmr, have been associated with ethambutol resistance. This review summarizes the molecular mechanisms underlying efflux-mediated EMB resistance, discusses laboratory methods used to identify efflux activity, and highlights the therapeutic potential of efflux pump inhibitors (EPIs) as adjunctive agents in TB treatment. Understanding efflux-mediated resistance provides new opportunities for developing improved diagnostic markers and novel therapeutic strategies against drug-resistant tuberculosis.

Keywords: *Tuberculosis, Ethambutol, Efflux Pumps, Drug Resistance, MDR-TB, embB Mutation, Efflux Pump Inhibitors.*

I. INTRODUCTION

Tuberculosis continues to be a major global health problem, with millions of new infections and over one million deaths annually. The increasing prevalence of MDR-TB and XDR-TB has become a significant challenge for public health systems worldwide. Ethambutol (EMB), introduced in the 1960s, is one of the four essential first-line anti-tuberculosis drugs used during the intensive phase of treatment.

Ethambutol specifically inhibits arabinosyl transferases responsible for synthesizing arabinogalactan and lipoarabinomannan, essential components of the mycobacterial cell wall. Resistance has traditionally been attributed to mutations in the embB306, embB406, and embB497 codons. However, several EMB-resistant clinical isolates lack these mutations, suggesting alternative resistance mechanisms.

One such mechanism involves bacterial efflux pumps. These membrane proteins actively export antibiotics from bacterial cells using ATP or proton motive force, thereby reducing intracellular drug accumulation. Increased expression of efflux pump genes has been documented in numerous EMB-resistant isolates, highlighting their important contribution to antimicrobial resistance.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, July 2026
Impact Factor: 8.2

II. ETHAMBUTOL MECHANISM OF ACTION

Ethambutol interferes with cell wall biosynthesis by inhibiting arabinosyl transferase enzymes encoded by the embCAB operon.

The consequences include:

1. Inhibition of arabinan synthesis
2. Defective arabinogalactan formation
3. Increased cell wall permeability
4. Arrest of bacterial growth
5. Enhanced susceptibility to companion anti-TB drugs

Because the mycobacterial cell wall is essential for bacterial survival, inhibition of its synthesis effectively suppresses bacterial multiplication.

Table 1. Mechanism of Action of Ethambutol

Target	Function	Effect of Ethambutol
EmbA	Arabinosyl transferase	Inhibits cell wall synthesis
EmbB	Arabinosyl transferase	Prevents arabinan polymerization
EmbC	Arabinosyl transferase	Disrupts lipoarabinomannan formation
Arabinogalactan	Cell wall component	Reduced synthesis
Cell Wall	Structural integrity	Weakens bacterial cell wall

III. EFFLUX PUMPS IN *MYCOBACTERIUM TUBERCULOSIS*

Efflux pumps are transmembrane transport proteins that remove toxic substances, including antibiotics, from bacterial cells.

Major efflux pump families include:

1. ATP Binding Cassette (ABC)
2. Major Facilitator Superfamily (MFS)
3. Resistance-Nodulation-Division (RND)
4. Small Multidrug Resistance (SMR)
5. Multidrug and Toxic Compound Extrusion (MATE)

Among these, MFS and ABC transporters are predominantly involved in mycobacterial drug resistance.

Table 2. Major Efflux Pumps Associated with Ethambutol Resistance

Efflux Pump Gene	Family	Energy Source	Role in Resistance
Rv1258c (Tap)	MFS	Proton motive force	Ethambutol export
efpA	MFS	Proton motive force	Multidrug resistance
mmr	SMR	Proton motive force	Low-level resistance
pstB	ABC	ATP	Drug transport
drrA	ABC	ATP	Multidrug efflux
Rv1819c	ABC	ATP	Ethambutol resistance

IV. MOLECULAR BASIS OF EFFLUX PUMP OVEREXPRESSION

Efflux pump overexpression occurs through several mechanisms:

1. Genetic Mutations

Mutations in promoter regions enhance transcription of efflux genes.

2. Environmental Stress

Exposure to sub-lethal concentrations of antibiotics induces transient efflux pump expression.

3. Regulatory Networks

Transcriptional regulators activate multiple efflux genes under drug pressure.

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, July 2026
Impact Factor: 8.2

4. Adaptive Resistance

Efflux-mediated resistance often precedes permanent chromosomal mutations.

Table 3. Factors Inducing Efflux Pump Expression

Factor	Mechanism	Outcome
Ethambutol exposure	Stress response	Increased pump expression
Oxidative stress	Gene activation	Enhanced drug efflux
Hypoxia	Dormancy response	Drug tolerance
Biofilm formation	Adaptive regulation	Persistent infection
Nutrient limitation	Global stress response	Increased survival

V. EVIDENCE SUPPORTING EFFLUX-MEDIATED ETHAMBUTOL RESISTANCE

Numerous molecular studies have demonstrated that EMB-resistant isolates exhibit significantly higher expression of efflux pump genes compared to susceptible strains.

Key findings include:

1. Increased expression of Rv1258c
2. Elevated efpA transcription
3. Upregulated pstB
4. Enhanced drrA activity
5. Increased intracellular drug export

Furthermore, treatment with efflux pump inhibitors such as verapamil, reserpine, and carbonyl cyanide m-chlorophenyl hydrazone (CCCP) restores EMB susceptibility in several resistant isolates.

Table 4. Experimental Evidence for Efflux Pump Overexpression

Observation	Experimental Method	Finding
Increased gene expression	RT-PCR	Higher mRNA levels
Reduced intracellular EMB	Drug accumulation assay	Active efflux observed
Lower MIC after EPI	MIC testing	Restored susceptibility
Enhanced ATP consumption	ATP assay	Active transport confirmed
Protein overexpression	Western blot	Increased pump production

VI. LABORATORY METHODS FOR DETECTING EFFLUX ACTIVITY

Several techniques are employed:

1. Real-Time PCR
2. RNA sequencing
3. Drug accumulation assays
4. Fluorescence-based transport assays
5. MIC reduction assays
6. Whole genome sequencing
7. Transcriptome analysis
8. Proteomics

Among these, quantitative RT-PCR remains the gold standard for measuring efflux gene expression.

Table 5. Detection Techniques

Technique	Principle	Advantage	Limitation
qRT-PCR	Gene expression	Highly sensitive	Requires RNA
RNA-Seq	Transcriptome analysis	Comprehensive	Expensive

DOI: 10.48175/568

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, July 2026
Impact Factor: 8.2

MIC assay	Drug susceptibility	Simple	Indirect
Fluorescence assay	Drug transport	Real-time	Specialized equipment
Whole Genome Sequencing	Mutation analysis	Comprehensive	High cost

VII. CLINICAL SIGNIFICANCE

Efflux-mediated resistance has several clinical implications:

1. Delayed treatment response
2. Increased treatment failure
3. Higher relapse rates
4. Evolution toward MDR-TB
5. Development of XDR-TB
6. Longer duration of therapy
7. Increased healthcare costs

Transient efflux-mediated resistance may allow bacteria to survive long enough to acquire stable chromosomal mutations, making early detection especially important.

VIII. EFFLUX PUMP INHIBITORS (EPIS)

Efflux pump inhibitors are compounds that block the activity of efflux transporters, thereby increasing intracellular antibiotic concentrations.

Common EPIs include:

1. Verapamil
2. Reserpine
3. CCCP
4. Chlorpromazine
5. Thioridazine

When combined with ethambutol, these agents have shown improved antimicrobial activity in laboratory studies, although their clinical application remains under investigation due to toxicity and pharmacological limitations.

Table 6. Efflux Pump Inhibitors Studied in *M. tuberculosis*

Inhibitor	Target	Effect on EMB Resistance	Current Status
Verapamil	ABC/MFS pumps	Reduces MIC	Experimental adjunct
Reserpine	MFS pumps	Restores susceptibility	Research use
CCCP	Proton motive force	Inhibits transport	Laboratory reagent
Chlorpromazine	Multiple pumps	Enhances EMB activity	Investigational
Thioridazine	Multidrug pumps	Synergistic activity	Experimental

IX. CONCLUSION

Efflux pump overexpression plays a significant role in ethambutol resistance among drug-resistant *Mycobacterium tuberculosis*. While mutations in the embCAB operon remain the principal mechanism of resistance, efflux pumps contribute to both transient and stable resistance by reducing intracellular drug concentrations. Overexpression of transporters such as Rv1258c, efpA, drrA, and pstB has been consistently observed in resistant isolates. Laboratory evidence demonstrates that inhibition of these pumps can restore ethambutol susceptibility, highlighting their potential as therapeutic targets. A comprehensive understanding of efflux-mediated resistance will support the development of improved diagnostic tools, novel adjunctive therapies, and more effective strategies for combating MDR-TB and XDR-TB. Continued research into efflux pump biology and inhibitor development is essential to enhance tuberculosis treatment outcomes and limit the global spread of drug-resistant disease.

IJARSCT
International Journal of Advanced Research in Science, Communication and Technology
International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal
ISSN: 2581-9429
Volume 6, Issue 4, July 2026
Impact Factor: 8.2

REFERENCES

1. Balganesh, M., Dinesh, N., Sharma, S., Kuruppath, S., Nair, A. V., & Sharma, U. (2012). Efflux pumps of *Mycobacterium tuberculosis* play a significant role in antituberculosis activity. *Antimicrobial Agents and Chemotherapy, 56*(5), 2643–2651.
2. da Silva, P. E. A., & Von Groll, A. (2011). Efflux as a mechanism for drug resistance in *Mycobacterium tuberculosis*. *FEMS Immunology & Medical Microbiology, 63*(1), 1–9.
3. Dai, X., Wu, H., Zhu, L., Chen, Z., Ma, W., Peng, L., Yang, R., Luo, S., Bao, F., & Liu, A. (2026). Global status of ethambutol resistance in *Mycobacterium tuberculosis* clinical isolates: An updated systematic review and meta-analysis. *Clinical Pediatrics, 32*(8).
4. Gupta, A. K., Katoch, V. M., Chauhan, D. S., Sharma, R., Singh, M., Venkatesan, K., & Sharma, V. D. (2010). Microarray analysis of efflux pump genes in multidrug-resistant *Mycobacterium tuberculosis*. *International Journal of Antimicrobial Agents, 36*(1), 63–68.
5. Jia, H., Chu, H., Dai, G., Cao, T., & Sun, Z. (2022). Rv1258c acts as a drug efflux pump and growth controlling factor in *Mycobacterium tuberculosis*. *Tuberculosis, 133*, 102172.
6. Kanji, A., Hasan, R., Hasan, Z., & Ali, A. (2017). Single nucleotide polymorphisms in efflux pump genes in extensively drug-resistant *Mycobacterium tuberculosis* isolates from Pakistan. *Tuberculosis, 107*, 20–30.
7. Liu, J., Shi, W., Zhang, S., Hao, X., Maslov, D. A., Shur, K. V., Bekker, O. B., Danilenko, V. N., & Zhang, Y. (2019). Mutations in efflux pump Rv1258c (Tap) cause resistance to pyrazinamide, isoniazid, and streptomycin in *Mycobacterium tuberculosis*. *Frontiers in Microbiology, 10*, 216.
8. Louw, G. E., Warren, R. M., Gey van Pittius, N. C., Leon, R., Jimenez, A., Hernandez-Pando, R., McEvoy, C. R., Grobbelaar, M., Murray, M., & van Helden, P. D. (2009). A balancing act: Efflux/influx in mycobacterial drug resistance. *Antimicrobial Agents and Chemotherapy, 53*(8), 3181–3189.
9. Machado, D., Couto, I., Perdigão, J., Rodrigues, L., Portugal, I., Baptista, P., Veigas, B., Amaral, L., & Viveiros, M. (2012). Contribution of efflux to the emergence of isoniazid and multidrug resistance in *Mycobacterium tuberculosis*. *PLoS ONE, 7*(4), e34538.
10. Oh, T. S., Kim, E., Yoo, H., Kim, H. J., Kim, C. K., Cho, S. N., & Lee, H. (2017). RNA expression analysis of efflux pump genes in clinical isolates of multidrug-resistant and extensively drug-resistant *Mycobacterium tuberculosis*. *Infection, Genetics and Evolution, 49*, 111–115.
11. Ramon-Garcia, S., Martin, C., Thompson, C. J., & Aínsa, J. A. (2009). Role of the *Mycobacterium tuberculosis* P55 efflux pump in intrinsic drug resistance, oxidative stress response, and growth. *Antimicrobial Agents and Chemotherapy, 53*(9), 3675–3682.
12. Ramon-Garcia, S., Ng, C., Anderson, H., Chao, J. D., Zheng, X., Pfeifer, T., Av-Gay, Y., & Thompson, C. J. (2012). Synergistic effect of efflux pump inhibition and antitubercular drugs against *Mycobacterium tuberculosis*. *Antimicrobial Agents and Chemotherapy, 56*(2), 967–970.
13. Rodrigues, L., Machado, D., Couto, I., Amaral, L., & Viveiros, M. (2012). Contribution of efflux activity to isoniazid resistance in the *Mycobacterium tuberculosis* complex. *Infection, Genetics and Evolution, 12*(4), 695–700.
14. Sharma, S., Kumar, M., Sharma, S., & Nargotra, A. (2010). Efflux pump inhibitors for bacterial pathogens: From bench to bedside. *Indian Journal of Medical Research, 131*(5), 649–657.
15. Srivastava, S., Musuka, S., Sherman, C., Meek, C., Leff, R., & Gumbo, T. (2010). Efflux-pump-derived multiple drug resistance to ethambutol monotherapy in *Mycobacterium tuberculosis* and the pharmacokinetics and pharmacodynamics of ethambutol. *Journal of Infectious Diseases, 201*(8), 1225–1231.